A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity

Relatively poor penetration and retention in tumor tissue has been documented for large molecule drugs including therapeutic antibodies and recombinant immunoglobulin constant region (Fc)-fusion proteins due to their large size, positive charge, and strong target binding affinity.